Erratum to Cardiovascular toxicity of anticancer-targeted therapy: Emerging issues in the era of cardio-oncology (Intern Emerg Med, 10.1007/s11739-011-0744-y);Cardiovascular toxicity of anticancer-targeted therapy: Emerging issues in the era of cardio-oncology

Internal and Emergency Medicine

Volumn 7, Issue 2, 2012, Pages 113-131

  Raschi, Emanuel ^a   de Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiotoxicity; Monitoring; Pharmacovigilance; Targeted therapy

Indexed keywords

EID: 84859435714     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-012-0762-4     Document Type: Erratum

References (80)

1. Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F (2010) Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 125: 196-218.
2. Force T, Krause DS, van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332-344.
3. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221.
4. Force T, Kolaja KL (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 10: 111-126.
5. Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T et al (2011) How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 163: 675-693.
6. Raschi E, Vasina V, Poluzzi E, De Ponti F (2008) The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res 57: 181-195.
7. Driver JA, Djousse L, Logroscino G, Gaziano JM, Kurth T (2008) Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ 337: a2467.
8. Ewer MS, Lenihan DJ (2008) Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 26: 1201-1203.
9. Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A et al (2007) An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117: 4044-4054.
10. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14-25.
11. Minotti G, Salvatorelli E, Menna P (2010) Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 334: 2-8.
12. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465-477.
13. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48: 9-17.
14. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9: 117-123.
15. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23: 460-468.
16. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011-2019.
17. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26: 3709-3714.
18. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S et al (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1432-1439.
19. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7: 475-485.
20. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24: 1363-1369.
21. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193.
22. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102: 596-604.
23. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46: 439-448.
24. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815.
25. Fonseca C (2006) Diagnosis of heart failure in primary care. Heart Fail Rev 11: 95-107.
26. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22: 3485-3490.
27. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10: 391-399.
28. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T et al (2010) Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 28: 3429-3436.
29. Cardinale D, Sandri MT (2010) Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53: 121-129.
30. Cheng H, Force T (2010) Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106: 21-34.
31. Hasinoff BB, Patel D (2010) The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol 249: 132-139.
32. Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23: 2900-2902.
33. Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25: 3525-3533.
34. Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Pritchard K et al (2009) Adjuvant targeted therapy in early breast cancer. Cancer 115: 1154-1168.
35. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
36. Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31: 459-467.
37. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820-7826.
38. Morris PG, Hudis CA (2010) Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol 28: 3407-3410.
39. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J (2011) Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. doi: 10. 1093/annonc/mdr294.
40. Ewer MS, Ewer SM (2010) Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol 28: 3901-3904.
41. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83: 679-686.
42. Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K et al (2007) Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA 104: 10607-10612.
43. FDA US Food and Drug Administration news release (2010) FDA begins process to remove breast cancer indication from Avastin label. http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm237172. htm. Accessed 20 September 2011.
44. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487-494.
45. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR et al (2011) Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29: 632-638.
46. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916.
47. Hatfield A, Owen S, Pilot PR (2007) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 13: 13-16.
48. Atallah E, Durand JB, Kantarjian H, Cortes J (2007) Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110: 1233-1237.
49. Ribeiro AL, Marcolino MS, Bittencourt HN, Barbosa MM, Nunes MC, Xavier VF et al (2008) An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 32: 1809-1814.
50. Estabragh ZR, Knight K, Watmough SJ, Lane S, Vinjamuri S, Hart G et al (2011) A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 35: 49-51.
51. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103: 553-561.
52. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53: 2231-2247.
53. ® (dasatinib) con l'Ipertensione Arteriosa Polmonare (PAH). http://www. sefap. it/farmacovigilanza_news_201109/sprycel_dhpc__28_jul_11_clean_aifa_rev_finale. pdf. Accessed 20 September 2011.
54. Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103: 1347-1348.
55. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL et al (2010) Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 120: 472-484.
56. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26: 5204-5212.
57. Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19: 1613-1618.
58. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C et al (2008) Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112: 2500-2508.
59. Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J (2007) Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 18: 1906-1907.
60. Fernandez A, Sessel S (2009) Selective antagonism of anticancer drugs for side-effect removal. Trends Pharmacol Sci 30: 403-410.
61. Burris HA, III, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD (2011) Trastuzumab Emtansine (T-DM1): a novel agent for targeting HER2(+) breast cancer. Clin Breast Cancer. doi: 10. 1016/j. clbc. 2011. 03. 018.
62. Carver JR (2010) Management of trastuzumab-related cardiac dysfunction. Prog Cardiovasc Dis 53: 130-139.
63. Ferrari N, Tosetti F, De Flora S, Donatelli F, Noonan DM, Albini A (2010) Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. Curr Drug Targets. Dec 15 (Epub ahead of print).
64. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36: 517-522.
65. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109: 2749-2754.
66. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28: 3910-3916.
67. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114: 2474-2481.
68. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De GG et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55: 213-220.
69. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM (2010) Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 56: 1644-1650.
70. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27: 4865-4873.
71. Hurwitz HI, Saltz LB, van CE, Cassidy J, Wiedemann J, Sirzen F et al (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29: 1757-1764.
72. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239.
73. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK (2011) Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 22: 1404-1412.
74. Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49: 287-297.
75. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300: 2277-2285.
76. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28: 2280-2285.
77. Seruga B, Sterling L, Wang L, Tannock IF (2011) Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 29: 174-185.
78. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH et al (2009) Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 27: 4398-4405.
79. Hauben M, Reich L, Chung S (2004) Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. Eur J Clin Pharmacol 60: 747-750.
80. Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F et al (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28: 3416-3421.